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Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a rare disease that may cause 
serious bleedings in the fetus or neonate of a woman who has developed antibodies against 
the fetus’ platelets. Development of FNAIT has been linked to the presence of platelet 
reactive CD4 T cells that help B cells to develop into antibody producing plasma cells. To be 
able to conduct research on such T cells, the Immunology research group must be able to 
expand and keep them in long term cultures. Recent work revealed that several established T 
cell clones had started proliferating poorly. In an attempt to understand why and to possibly 
improve the culturing of future T cell clones, this study looked into some of the conditions 
that may influence the growth of these cells when expanded in vitro. The established anti-
CD3 expansion culture protocol was compared to one that used PHA, but no advantage of 
using the latter was detected. It was demonstrated that different B-LCLs used as growth 
promoting feeder cells expressed varying levels of the surface molecules B7-1 and B7-2. This 
did however not seem to influence their feeder capacity despite the fact that expanding CD4 T 
cells were shown to express high levels of CD28, which costimulates growth when bound by 
B7. Expanding CD4 T cells also expressed the inhibitory molecule PD-1, and it was revealed 
that expression of its ligand, PD-L1, was induced in B-LCLs when used as feeder cells along 







All living species are at risk of being infected by diseases, which may cause illness or even 
death. Over the course of evolution, most species have therefore developed advanced systems 
to protect against disease. Specialized cells, tissues and molecules together make up the 
immune system, whose role is to recognize infectious agents and then eradicate them, thereby 
creating resistance to disease (1). In humans and other jawed vertebrates, the immune system 
consists of two branches: innate and adaptive immunity (1, 2).  
Innate immunity is based on the recognition of molecular structures that are present on 
microorganisms (1, 2). Detection of these structures leads to an immune response mediated by 
certain cell types, including different phagocytes, dendritic cells and natural killer cells, as 
well as by the enzymatic proteins of the complement system that are able to kill microbes. 
Physical barriers created by epithelial cells are also part of the innate immunity (1). 
The adaptive immunity, also called acquired immunity, develops more slowly compared to 
the innate, but is more specialized (1). This branch of immunity is mediated by T and B 
lymphocytes, which are cells that express antigen receptors. The antigens can be various types 
of proteins or other molecules expressed by foreign microbes. Somatic recombination of the 
genes encoding the antigen receptors in T and B cells leads to a great repertoire of different 
receptors, and each individual T or B cell clone expresses its own unique receptor. The 
repertoire of different T and B cells increases with age and as an individual is affected by 
different diseases throughout their lifetime. This is why this branch of the immune system is 
called adaptive or acquired (1).  
T and B cells play different roles in the immune response against a foreign microbe. Two 
main types of T cells exist: cytotoxic CD8 T cells that kill virus infected or damaged cells and 
CD4 helper T cells that help B cells to start secreting antibodies. Antibody is the name of a B 
cell receptor when it is released into circulation. Circulating antibodies recognize the antigen 
that they are specific for, which normally leads to destruction of the microbe expressing the 
antigen. This can for instance happen through phagocytosis by a macrophage (1). 
Despite the fact that the immune system is a remarkable part of our bodies that protects us 
from an array of infectious diseases, it can also play against our advantage in some cases. 




individual. In some rare cases this can happen during pregnancy, where the mother’s immune 
system attacks an antigen expressed in the fetus. This is the case with fetal and neonatal 
alloimmune thrombocytopenia (FNAIT). 
 
1.1 Fetal and neonatal alloimmune thrombocytopenia 
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a condition that can affect the 
fetus or neonate of a woman who has developed antibodies specific for the platelets of the 
child (3).The antibodies cross the placenta during pregnancy and bind to the fetal platelets, 
causing their destruction, which then results in thrombocytopenia (deficiency in platelets) in 
the fetus (4). Since platelets play an essential role in blood clotting, thrombocytopenia can 
cause bleedings in the fetus, with the most severe and feared consequence being intracranial 
hemorrhage and possible death (4). Severe FNAIT is defined as a platelet count of <20 x 109 
per liter of blood in the infant, and this occurs at a frequency of 1 in 1000 to 2000 births (4). 
In most cases of FNAIT, the maternal antibodies bind to an epitope on integrin β3 on the 
platelet surface, which is known as human platelet antigen 1 (HPA-1) (3). The epitope is 
defined as a single amino acid difference at residue 33 of integrin β3. The most common 
variant is to have a leucine at this position, which is called HPA-1a, and 98% of Caucasians 
carry this variant (4). Another variant, called HPA-1b, has a proline at position 33. About 2 % 
of women are homozygous for the proline variant (HPA-1bb) and if these women become 
pregnant with a fetus that has inherited the HPA-1a variant from their father, they are in 
danger of developing antibodies against the fetal platelets (4). This is because the maternal 
immune system perceives the fetal platelets as a foreign invader. There exists other HPA 
genes that can also lead to development of FNAIT, but the HPA-1 incompatibility is certainly 
the most common in western countries, accounting for approximately 80 % of cases in 
Caucasians (5). FNAIT caused by HPA-1a is therefore the main focus at the Immunology 
research group. 
1.1.1 Cellular mechanisms involved in FNAIT 
Since FNAIT is caused by antibodies, there are certain cellular mechanisms that are likely to 
be involved in the development of this disease. Antibodies are produced by plasma cells, 
which have developed from B cells that have recognized foreign antigens. Normally, B cells 




activated and become an antibody producing plasma cell. T and B cells are activated 
separately and then come together in lymphoid follicles (1).  
An immune response leading to production of antibodies starts when a foreign microbe, or in 
this case, a foreign platelet, enters the body. Exactly how this happens in FNAIT is not fully 
understood. Normally, fetal and maternal blood does not mix during pregnancy (6), so the 
mother’s immune cells would not come in contact with the fetal platelets. However, some 
have suggested that due to the small size of platelets, they may be able to leak into the 
maternal circulation (7). Another possibility is that the immunization occurs as a consequence 
of fetal-maternal bleeding during birth, which would only lead to FNAIT in a subsequent 
pregnancy (7, 8). Yet another possible mechanism of immunization includes exposure of the 
antigen, HPA-1a on integrin β3, to the maternal immune system by other cell types than 
platelets. Integrin β3 has in fact been shown to also be expressed by trophoblast cells in the 
placenta, which have developed from fetal cells, but are in contact with the maternal blood 
circulation (6). Spermatozoa have also been shown to express integrin β3 and may cause 
antigen exposure before pregnancy (7, 8).  
Regardless of how the mother’s immune system comes in contact with the HPA-1a antigen, 
this contact starts an immune response. Dendritic cells are a type of immune cells that express 
various membrane receptors that they use to recognize foreign microbes, or platelets in this 
case, and when they do, they ingest the foreign agent by endocytosis (1). The dendritic cells 
are so-called professional antigen presenting cells (APC), which break down the ingested 
material to fragments that are presented on the surface of the cell. Antigens from extracellular 
microbes or cells that have been endocytosed are presented on major histocompatibility 
complex class II (MHC II) molecules. At this point the dendritic cells simultaneously start to 
migrate to nearby lymph nodes (1). 
Naïve T cells continuously circulate through the peripheral lymphoid organs in our body, and 
when they enter a lymph node, they may encounter a dendritic cell that presents antigen on 
MHC II molecules. Helper T cells express the coreceptor CD4, which binds to MHC II. In 
addition, each T cell has its own T cell receptor (TCR) with a certain specificity that can 
recognize a specific foreign antigen. If a T cell recognizes antigen presented by a dendritic 
cell it can become activated (1).  
Naïve B cells, like T cells, also express receptors that can recognize antigen. The receptors are 
molecules called immunoglobulins (Ig), which when bound to the surface of the cell function 




that function as receptors are of class M and D (IgM and IgD). The majority of B cells are 
follicular B cells, which circulate through the follicles of lymphoid organs. There, they may 
recognize antigens that have been transported to the follicles. Recognition of antigen, along 
with some other signals, initiates an activation process in the B cell, which leads to 
proliferation and differentiation. Protein antigens make B cells more able to interact with T 
lymphocytes. Protein antigens are also endocytosed and displayed on MHC II by the B cells, 
which migrate into the areas of the lymphoid organs where helper T cells reside. The helper T 
cells are then able to recognize the antigen presented by the B cell if they have previously 
been activated by a dendritic cell presenting the same antigen (Figure 1). The activated CD4 
helper T cells express CD40 ligand, which can bind to CD40 on the B cells. This interaction 
stimulates proliferation and antibody production as well as isotype switching, which is a 
process where the B cells can start to produce other classes of immunoglobulins than IgM and 
IgD. IgG is the immunoglobulin class that is associated with phagocytosis of foreign agents 
by neutrophils and macrophages. IgG antibodies also have the special ability to bind to a 
receptor expressed in the placenta called the neonatal Fc receptor (FcRn), which makes it 
possible for IgG antibodies specific for HPA-1a to be transported from maternal blood to a 
fetus during pregnancy (1, 9). Production of IgG antibodies is stimulated by the cytokine 
interferon-γ (IFNγ), which is typically secreted by a subclass of helper T cells called T helper 
1 (TH1) cells. Antibody producing B cells can eventually mature into fully differentiated 
plasma cells that can survive for years and secrete antibodies while circulating through the 
body. 
 
Figure 1 A CD4 helper T cell that has been activated by an APC presenting the HPA-1a antigen encounters a B 
cell that has recognized HPA-1a on a fetal platelet, endocytosed the platelet and is presenting the HPA-1a 
antigen on MHC class II. This leads to activation of the B cell, which differentiates into a plasma cell secreting 






1.2 Human leukocyte antigen 
Interestingly, not all HPA-1bb women who become pregnant with HPA-1a positive children 
develop the platelet reactive antibodies. In most cases, other aspects also seem to play 
important roles, such as the MHC genes of the mother. The gene complex that contains the 
genes encoding MHC molecules is called the human leukocyte antigen (HLA) complex (1). 
The genes encoding MHC II molecules are called HLA-DP, HLA-DQ, and HLA-DR. Each 
individual carries one pair of HLA-DP genes (DPA1 and DPB1), one pair of HLA-DQ genes 
(DQA1 and DQB1), one HLA-DRα gene (DRA1) and one or two HLA-DRβ genes (DRB1 
and DRB 3, 4 or 5) on each chromosome (1). The genes on both chromosomes, one inherited 
from the mother and one from the father, are expressed equally. There exists numerous 
different variants (alleles) of each of the HLA genes, which leads to great variability in the 
HLA gene complex among different individuals. The different alleles have numeric names 
that are used to describe the HLA complex of a certain individual (1). 
It has been shown that over 90 % of the women who produce anti-HPA-1a antibodies carry 
the HLA-DRB3*01:01 allele, whereas this allele is only present in less than 30 % of the 
general population (4, 10). The HLA-DRB3*01:01 allele together with HLA-DRA encode the 
MHC II molecule HLA-DR52a (9). It is believed that the CD4 T cells involved in the 
production of antibodies in FNAIT are restricted to only recognizing peptides presented on 
the HLA-DR52a MHC molecule. Each MHC molecule has a peptide binding groove, where 
the peptide antigens that they present are attached and only peptides that fit in this groove can 
be presented (1). Since there is such a strong connection between the HLA-DRB3*01:01 allele 
and the production of antibodies in FNAIT, the general belief is that the leucine present in 
position 33 in integrin β3 on the fetal platelets must be present in the peptide that is presented 
to the CD4 T cells (9).  
In an article from 1997 it was shown that a peptide derived from integrin β3 containing the 
leucine at position 33 could bind to the HLA-DR52a MHC molecule, whereas a peptide with 
proline in this position that was otherwise identical was not able to bind (11). The same article 
suggested that the leucine in position 33 works as an anchor residue for binding to HLA-
DR52a along with two other amino acids. When leucine is exchanged for a proline and the 
peptide is no longer able to bind HLA-DR52a, it is believed that this is because the 
hydrophobic residue of leucine can function as an anchor residue, but the polar proline 





1.3 Immune checkpoint molecules 
In addition to the recognition of an MHC-peptide complex, other interactions can occur 
between a T cell and an APC. These interactions can be either stimulatory or inhibitory, and a 
balanced expression of these molecules is needed to maintain self-tolerance and prevent 
autoimmunity (12). The receptors and ligands involved in these types of interactions are 
called immune checkpoint molecules. 
1.3.1 Costimulation 
During the activation of a naïve T cell the recognition of peptide presented on MHC is 
referred to as signal 1, but a second signal is also required for activation. Signal 2, also 
referred to as costimulation, usually involves interaction of the surface marker CD28, 
expressed by the vast majority of T cells, with the ligand B7-1 (CD80) or B7-2 (CD86), 
which is expressed by APCs (1). The expression of B7 is upregulated in APCs when they 
encounter microbes or other foreign cells. When activated by antigen and costimulators, the 
transcription of genes encoding interleukin-2 (IL-2) and IL-2-receptor components starts in T 
cells. The main function of IL-2 is to stimulate survival and proliferation of T cells (1). 
1.3.2 Inhibitory checkpoint molecules 
Interestingly, B7-1 and B7-2 are stronger ligands for a receptor called cytotoxic T lymphocyte-
associated protein 4 (CTLA4) than for CD28. CTLA4 negatively effects T cell responses, but 
is not constitutively expressed (1, 13, 14). CTLA4 is an inhibitory checkpoint molecule. 
Expression of CTLA4 on the surface of T cells is tightly regulated and it is practically only 
expressed by fully activated T cells, memory and regulatory cells (14).  
Several other inhibitory checkpoint molecules exist and another example is programmed cell 
death protein 1 (PD1) (12, 13). PD1 is structurally similar to CTLA4 (15), and when it is 
engaged, the cell cycle is arrested and production of IL-2 is significantly reduced, leading to 
inhibition of proliferation. Resting T cells do not express PD1, but activation of T cells 
through the TCR or with other stimulants results in PD1 expression (13, 15). PD1 has two 
ligands: PD-L1 and PD-L2, which both inhibit proliferation but have different expression 
patterns. PD-L1 is mainly expressed by various antigen presenting cells, but not 
constitutively. Resting B cells do not express PD-L1, but its expression can be induced by 
activation through the BCR (13, 15). Expression of PD-L2 on the other hand is quite 
restricted and is not associated with expression by B cells, but it can be expressed by dendritic 




Other examples of immune checkpoint molecules expressed by T cells include lymphocyte-
activation gene 3 (LAG3) and T cell immunoglobulin and mucin-domain containing 3 
(TIM3), which bind to MHC and galectin-9 (GAL9) on APCs respectively (12). Figure 2 
summarizes some of the most important immune checkpoint molecules. 
 
 
Figure 2 Recognition of a peptide antigen presented on MHC class II by an antigen presenting cell is the first 
signal needed for activation of a CD4 T cell. Interaction of B7 with CD28 can provide the second signal needed 
for activation. B7 can also be bound by CTLA4, which has an inhibitory effect on the T cell. LAG3, PD1 and 
TIM3 inhibit T cell proliferation if bound by their ligands MHC II, PD-L1 and GAL9 respectively. 
 
1.3.3 Immune checkpoint molecules in cancer 
Since the discovery of inhibitory checkpoint molecules and their ligands, it has been found 
that several cancer cells can express these ligands and engage the corresponding receptors on 
T cells. In this way, the cancer cells inhibit the proliferation of tumor infiltrating T cells and 
thereby resist their immune response (12). This knowledge has again led to the development 
of new cancer treatments that block these types of interactions between cancer cells and T 
cells. The blockade can either be accomplished by administering antibodies to the cancer that 
block the receptors on the T cells, so that they cannot be engaged, or the genes encoding the 
receptors can be knocked out for instance by the use of CRISPR/Cas gene-editing (12, 18). 
The first immune checkpoint receptor to be clinically targeted was CTLA4 (12). Promising 
results were obtained with CTLA4 specific antibodies and one such drug has been approved 
by the US Food and Drug Administration for treatment of advanced melanoma (12). 




promising effects (12). Antibodies targeting both PD1 and PD-L1 are continuously being 
tested, and PD1 knockout T cells have been generated and proven to show increased T cell 
effector function (12, 19). Cancer immunotherapy directed towards PD1 or PD-L1 blockade is 
a research area that is currently receiving enormous amounts of attention. 
1.3.4 Anergy 
In the absence of a costimulatory signal, naïve T cells do not become activated. Interestingly, 
absence of this interaction is however not a neutral event, but can have a negative effect on T 
cell survival. A T cell that recognizes antigen presented on MHC, but does not simultaneously 
receive a costimulatory signal may enter a state of unresponsiveness called anergy (20). T cell 
anergy is a state where T cells maintain their morphology, but their ability to produce IL-2 is 
repressed, consequently preventing the cells from proliferating. Their ability to proliferate 
must however also be affected in another way as exogenous IL-2 can not prevent anergy (20). 
If anergic cells again are exposed to antigen as well as a costimulatory signal, they still do not 
respond. It is however important to note that the anergic state has been reversed in vitro by 
stimulating the cells with high concentrations of IL-2 (20). 
1.3.5 Immunosenescence 
Even if a cell does not become anergic during its lifetime, it will still eventually lose its 
proliferative capacities as it ages. Since lymphocytes have an extremely high replicative rate, 
it may be due to loss of telomerase activity, which is an enzyme that elongates the DNA to 
protect it from shortening during replication (21). Other signs of aging in CD4 T cells include 
low production of IL-2, low response to IL-2, high response to IL-15 and loss of expression of 
CD28. When T cells recognize antigen, CD28 is downregulated quickly, but then returns to 
normal. However, with sustained stimulation over time, the expression of CD28 is decreased 
and may be lost. These cells are called CD28null cells and they tend to accumulate in elderly 
individuals (21). Despite the fact that CD28 is lost, the cells remain functionally active and 
are resistant to apoptosis (21). 
 
1.4 Culturing of T cells in vitro 
All of the cellular interactions involving different immune cells that have been described until 
now are important to know about to be able to understand how the immune system functions 




vitro. Still, there are many mechanisms and interactions involved in the culturing of T cells 
that are being explored. 
1.4.1 Restimulation and the role of CD28 
As previously explained, the initial activation of a T cell happens when it encounters an APC 
presenting the antigen that it is specific for. This leads to a massive expansion of the T cell. 
After the immune response is over, most of the T cells involved in it die (1). Some of the T 
cells do however differentiate into long-lived memory cells which do not have any effector 
properties any more, but can be reactivated and again expand to high numbers of effector 
cells. This happens if the memory cell encounters the same antigen again. This process is 
called restimulation (1). 
When culturing CD4 T cells in vitro, they can be expanded by subjecting them to a false 
restimulation. A frequently used way of doing this is not to expose the cells to antigen, but 
instead stimulate them with anti-CD3 antibodies. The antibodies bind to the TCR-CD3 
complex and activate the signaling pathways that are normally initiated by antigen recognition 
by the TCR, which in turn leads to proliferation (22). 
Whether or not the second signal, binding of CD28 to B7, which is required in the initial 
activation of a naïve T cell, is necessary for restimulation is unclear. For a long time, the 
general opinion was that CD28 plays no role in restimulation of T cells (23, 24). However, 
more recent research has shown that it probably does play a role after all (14, 25). A study 
from 2006 showed that when CD28 costimulation was blocked in memory T cells by an 
antibody binding to B7, their production of IL-2 and TNFα decreased (25). A study from 
2009 by a different group, which looked at CD8 T cells, found that when CD28 costimulation 
was blocked, the re-expansion of memory cells was significantly reduced (14). The same 
study also showed that memory CD8 T cells that were generated in the absence of CD28 
stimulation were only able to expand approximately 9 times, whereas memory cells generated 
with CD28 stimulation expanded more than 40 times (14). Because of this, many groups use 
anti-CD28 antibodies in addition to anti-CD3 when expanding T cells in vitro (22, 26). 
1.4.2 Using PHA as stimulant in expansion cultures 
An optional way of expanding T cell in vitro is to use stimulatory lectins, such as the plant 
lectin phytohemagglutinin (PHA) instead of anti-CD3. PHA does not specifically bind to only 
CD3, but is able to bind to many cell membrane glycoproteins, including the TCR-CD3 




reported as a more potent stimulant than soluble anti-CD3 (22, 27). It is however important to 
note that as anti-CD3 only leads to activation of the TCR this provides a more physiologically 
relevant response than PHA, which unspecifically activates several different pathways in T 
cells (22). PHA is not able to activate any other cell types than T cells (28).  
1.4.3 Feeder cells 
When expanding T cells, it is common to culture them along with so-called feeder cells. 
These can for instance consist of peripheral blood mononuclear cells (PBMCs) and B 
lymphoblastoid cell lines (B-LCLs) that have been exposed to irradiation and thereby have 
lost their ability to grow and proliferate, but remain viable and bioactive (29). This means that 
they are able to provide important survival signals for the T cells at the same time as they 
create a dense cell layer, which promotes growth of the T cells (29). Using feeder cells to 
expand another cell type is a widely used method within many different fields. Different cell 
types can be used as feeder cells and their proliferation can be inhibited using different 
methods (29).  
The first use of feeder cells to promote the growth of single cell clones was reported in 1955 
by Puck and Marcus (30). They used x-irradiated HeLa cells as feeder cells to grow other 
clones of HeLa cells. The irradiated HeLa cells did not seem to undergo any change during 
the first 48-72 hours, but then started to degenerate and form debris. They found that the non-
irradiated cells grew steadily and formed colonies whereas the irradiated cells did not. Puck 
and Marcus concluded that this method could be used to form colonies from almost all single 
HeLa cells and that it could probably be used on other cell types as well. They did however 
not know exactly what the growth promoting factor was (30). 
Using irradiated PBMCs and B-LCLs as feeder cells when expanding T cell clones is a 
method that is routinely used at the Immunology research group for the expansion of CD4 T 
cell clones and it has worked well for many years. However, the exact mechanisms by which 
these cells promote growth of the T cells are not known. Exactly what happens to the PBMCs 
and B-LCLs when they are irradiated is not known either. The general opinion is that 
irradiation creates double stranded breaks in the DNA, which inhibits replication, but still 
leaves the cell metabolically active for a while (30, 31). In this state, the feeder cells can 
release growth factors to the culture medium and express various ligands that help the T cells 




A population of PBMCs consists of several different cell types, including B cells. Knowing 
this, it would perhaps seem unnecessary to use B-LCLs in addition to PBMCs as feeder cells. 
However, in the early 1980’s, a research group from the Netherlands performed some 
experiments to test various factors that could play a role in the efficiency of CD8 T cell clone 
expansion (33). They used irradiated PBMCs and B-LCLs as feeder cells. They found, among 
other things, that using PBMCs and B-LCLs together as feeder cells led to significantly better 
growth of the CD8 T cells than by the use of only one of the feeder cell types alone. The 
explanation for this observation was however not found. They also found that different B-
LCLs had varying abilities to promote growth of the CD8 T cells. Some of their B-LCLs led 
to significantly better growth of the T cells and when these B-LCLs were combined in one 
expansion reaction, the growth was even better (33). 
One way that feeder cells stimulate growth of other cells is that they express stimulatory 
ligands that can interact with the growing cells (32, 34). In the case of T cells cultured with B-
LCL feeder cells, one such interaction could be between B7 on the B-LCL and CD28 on the T 
cells. However, it is important to note that if the B-LCLs express B7, this could also bind to 
CTLA4 and have an inhibitory effect on T cells if they are expressing CTLA4. There may 
also be several other negative interactions that can occur in such a co-culture system. Other 






1.5 Current research and aims of the study 
The Immunology research group has been conducting research on FNAIT and the cellular 
processes involved in the disease for many years (4, 10, 35-38). In 2008, they managed to 
isolate the first HPA-1a-specific T cells from an HPA-1a-alloimmunized woman and prove 
that these cells became activated upon stimulation with HPA-1a (37). Several other HPA-1a-
specific T cells were subsequently isolated and expanded in vitro to use in experiments (10).  
To be able to conduct research on HPA-1a specific CD4 T cell clones, the Immunology 
research group is dependent on keeping these cells in long-term cultures. The T cell clones 
need to be expanded to high numbers so that the same cell line can be used in multiple 
experiments. This should be accomplished in a way that does not alter the characteristics of 
the specific T cell line. The current protocol for this type of expansion involves culturing the 
T cells with growth inhibited feeder cells and anti-CD3. In addition, the growth promoting 
cytokines IL-2 and IL-15 are added. 
However, during the early work with this project, it was discovered that some of the 
established CD4 T cell lines would not grow as well as they previously had. It became harder 
to expand these cell lines using the protocol that previously had worked very well.  
With this in mind, the primary objective of this study became to investigate the culturing 
conditions that the CD4 T cell lines normally are grown under to try to understand what may 
be the cause of the reduced proliferation.  
Secondary objectives included: 
− Comparison of the stimulatory effects of anti-CD3, PHA and different feeder cells 
− Characterization of B-LCLs used as feeder cells and of CD4 T cells in expansion 
cultures 
− Attempted isolation and establishment of new HPA-1a specific T cell lines for the 







2 Methods and Materials 
2.1 Materials and reagents 
All mediums, buffers and reagents used during this study are listed in Table 1. Fluorophore-
conjugated antibodies are listed in Table 2. 
 
Table 1 Mediums, buffers and reagents used in this study 
Name Distributor Usage 
Phosphate Buffered Saline (PBS) Medicago (Uppsala, Sweden) Washing 
PBS + 0.2% Bovine Serum Albumin (PBSA 0.2%) Washing, Flow 
cytometry 
Iscove’s Modified Dulbecco Medium (IMDM) Lonza (Basel, Switzerland) Cell culture 
Fetal Bovine Serum (FBS) Thermo Fisher (Waltham, MA) Cell culture 
Penicillin-Streptomycin  Sigma (St. Louis, MO) Cell culture 
IL-2 PreproTech (London, UK) Cell culture 
IL-15 PreproTech Cell culture 
CFSE, CellTrace Thermo Fisher Flow cytometry, 
FACS 
Dimethyl Sulfoxide (DMSO) Wak-Chemie Medical GmbH (Steinbach, 
Germany) 
Cryopreservation 
LymphoprepTM Axis-Shield, Dundee, Great Britain PBMC isolation 
Anti-CD3 Thermo Fisher Cell culture 
PHA (R30852801) Thermo Fisher Cell culture 
UltraComp eBeads Thermo Fisher Flow cytometry 





Table 2 Complete list of fluorescently labeled antibodies used in this study 
Target Conjugate Distributor Reference Amount (µl) 
used in 100 
µl reaction 
Usage 
CD4 V500 Becton Dickinson 860768 2.5 Flow cytometry, 
FACS 
CD25 PE Becton Dickinson 555432 10 FACS 
HLA-DR APC BioLegend (San Diego, 
CA) 
307610 1 Flow cytometry 
PD1 PE Biolegend 329906 2 Flow cytometry 
CD274 eFluor 450 Thermo Fisher 48-5983-42 2 Flow cytometry 
CD86 R-PE Thermo Fisher MHCD8604 0.75 Flow  cytometry 
CD80 FITC Invitrogen 11-0809-42 2 Flow  cytometry 
CD28 PE-Cy7 Thermo Fisher 25-0289-42 2 Flow  cytometry 
CTLA4 APC Becton Dickinson 555855 2 Flow  cytometry 
 
Some experiments used peptides for specific activation of T cells. These were obtained from 
Eurogentec (Liège, Belgium) and are listed in Table 3. The peptides were from integrin β3, 
with either a leucine or a proline in position 33 as is the case on HPA-1a and HPA-1b 
platelets respectively. LolP1 was used as a control peptide as it is known to bind to the HLA-
DRA/DRB3*01:01 molecule and has the same anchor residues as the HPA-1a peptide but is 
otherwise different (11). The peptides were dissolved in 60% ethanol and 40% water to 88 
µM an stored at –20°C. 
 
Table 3 Peptide antigens used in this study 
Antigen Peptide Amino acid sequence* Length 
HPA-1a L33 (integrin β3 19-38, Leu33) VSPMCAWCSDEALPLGSPRC 20-mer 
HPA-1b P33 (integrin β3 19-38, Pro33) VSPMCAWCSDEALPPGSPRC 20-mer 
Rye Grass Pollen LolP1 (191-210) ESWGAVWRIDTPDKLTGPFT 20-mer 






The study was approved by the Regional Committee for Medical Research Ethics, North-
Norway (approval no. P REK NORD 66/2005). 
Technical blood products from healthy volunteers consenting to their blood being used for 
research purposes were obtained from the Blood Bank at the University Hospital of North 
Norway (not requiring REK approval). 
2.2.1 T cells 
The HPA-1a specific CD4 T cell clone D8T106 that was used during this study had been 
previously isolated and cryopreserved at the Immunology research group (10). 
Some experiments used a mix of CD4 T cells from PBMCs, isolated by positive selection 
magnetic-activated cell sorting (MACS). Previously isolated PBMCs from anonymous donors 
(method described later) were stained with CD4 microbeads (130-045-101, Miltenyi Biotec, 
Bergisch Gladbach, Germany) and isolation was carried out according to the manufacturer’s 
protocol except that PBSA 0.2 % was used instead of the recommended buffer. 
2.2.2 B LCLs 
A panel of eight different B-LCLs were thawed for use during this project, both as feeder 
cells and as APCs (Table 4). These are B cell lines that are able to process and present 
antigen, and that have been transfected with Epstein-Barr virus (EBV), which makes them 
immortal (39).  
The majority of the B-LCLs used are in-house cell lines, isolated from HPA-1a immunized 
women. This means that these cells are all HPA-1a negative, which makes them suited to use 
as APCs in experiments with HPA-1a specific T cells since HPA-1a positive APCs could lead 
to activation of sensitive clones (10). All the in-house cell lines also carry the HLA 
DRB3*01:01 allele, which, as previously explained, is greatly associated with FNAIT (9). 
Two of the B-LCLs are obtained from the International Histocompatibility Working Group 
(IHWG, Seattle, WA). The STEINLIN cell line also carries the HLA DRB3*01:01 allele, and 
is in fact homozygous for it. STEINLIN is the only B-LCL that is HPA-1a positive whereas 
EMJ is the only B-LCL that does not carry the HLA DRB3*01:01 allele. 
When B-LCLs were used as APCs they first had to be pulsed with peptide. This was 
performed by incubating the cells with the peptide at the desired concentration for 




Table 4 All B-LCLs used during this project 
Name Origin HLA-DRB3 
D4BL4 In-house 01:01 
D18BL In-house 01:01 
D8BL7 In-house 01:01 
D8BL8 In-house 01:01 
D48BL4 In-house 01:01 
D48BL6 In-house 01:01 
EMJ IHW no. 9097 03:01 
STEINLIN IHW no. 9087 01:01 
 
2.3 Cryopreservation 
Cryopreservation is a method that enables the storing of cells for several years without having 
to keep them in culture. The cells are suspended in a protective medium and then cooled to 
very low temperatures and later stored in liquid nitrogen tanks holding –196°C. At any time 
the cells can be thawed again and used in experiments. 
To prepare cells for cryopreservation, they were spun down and resuspended in freeze 
medium consisting of 90 % FBS and 10 % DMSO. The concentration of cells per ml varied, 
but was usually between 5 and 10 x 106. Cryo vials were then filled with 1.5 ml cell 
suspension and transferred to a pre-cooled Mr. Frosty freezing container (Sigma). The 
container was put in –70°C and the vials were later transferred to liquid nitrogen tanks. 
Thawing of cryopreserved cells was done by immediately transferring the tubes from the 
nitrogen tank to a water bath holding approximately 50 °C and keeping them there until only 
a small clump of solid ice remained. This clump was thawed by finger warming the tubes and 
then the cells were immediately transferred to a 15 ml conical vial containing 10 ml cool 
culture medium. The cells were spun down once and then resuspended in fresh medium.  
 
2.4 Cell culturing 
All cells were cultured in IMDM completed with 10% FBS and 1% penicillin + streptomycin. 




3% human serum from HPA-1a negative donors. The cells were kept in culture flasks or 
plates at 37°C with 7.5% CO2. Since the B-LCLs are EBV-transformed, they grow 
autonomously and do not need to be stimulated to grow, but they were regularly split and 
provided with fresh medium. T cell clones had to be stimulated in expansion cultures to make 
them proliferate. 
The human serum was prepared from plasma from HPA-1a negative donors provided by the 
blood bank. CaCl2 was added to the plasma at a 1:100 ratio and the plasma was put at 37°C 
over night. The next day, the liquid that had not formed clumps was transferred to tubes and 
centrifuged for 15 minutes at 3000 g. The supernatant contained the serum, which was filtered 
and transferred to a new tube. The serum was then heat-inactivated by putting it in a water 
bath holding 56°C for 25 minutes. The serum was kept at –70°C and thawed when needed for 
preparation of medium. 
 
2.5 Expansion of T cell lines 
T cells were expanded with feeder cells and soluble anti-CD3. The expansion cultures were 
normally kept in 24-well plates, starting with approximately 500 000 T cells per well. Each 
well was supplied with feeder cells consisting of approximately 4 x 106 irradiated PBMCs and 
1 x 106 irradiated B-LCLs. The PBMCs had previously been isolated as described below. 
Each well was filled to 2 ml with medium containing anti-CD3 to make the final 
concentration in each well equal to 30 ng/ml. The following day IL-2 was added to the T cells 
at a concentration of 50 units/ml. This was repeated every other or every third day. 
After 10-14 days, the dead feeder cells were removed by resuspending all cells in 5 ml 
complete medium and then layering the cell suspension over 5 ml LymphoprepTM in a 15 ml 
conical tube. The tube was centrifuged at 800 g for 8 minutes with minimal acceleration and 
no brakes. The cell layer visible between the LymphoprepTM and medium contained the live 
cells and was transferred to a new tube. They were washed two or three times in 0.2% PBSA 
or medium before they could be cultured further or used in experiments. 
2.5.1 Expansion with PHA 
In some expansion cultures PHA was used as stimulant instead of anti-CD3. The protocol for 
this was obtained from colleagues in Amsterdam. These expansion cultures were also kept in 




LCLs, but at a concentration of 1 x 106 and 100 000 cells per well respectively. Between 200 
000 and 300 000 T cells were added to each well. The medium used was the same as for the 
anti-CD3 expansion, but with added PHA at a concentration of 0.8 µg/ml instead of anti-CD3. 
IL-2 was added to the cultures the next day at a concentration of 120 units/ml and then again 
approximately every third day. 
2.5.2 Expansion in smaller volumes 
In some experiments 48- or 96-well plates were used for expansion of T cells, either 
following the anti-CD3 or the PHA protocol. If 48-well plates were used for expansion, all 
cell numbers were halved and the volume per well was 1 ml. In flat-bottom 96-well plates, the 
cell numbers were divided by 6.25 and the volume in each well was 200 µl. 
 
2.6 Isolation of PBMCs 
Blood buffy coats were obtained from the blood bank. 50 ml conical tubes were filled with 12 
ml LymphoprepTM and approximately 25 ml buffy coat, diluted 1:1 in PBS, was carefully 
layered on top. The tubes were then centrifuged for 25 minutes at 800 g with no brakes and 
minimal acceleration. The PBMCs, which were visible as a thin white layer on top of the 
LymphoprepTM (see Figure 3), were transferred to a new 50 ml conical vial by the use of a 
Pasteur pipette. The PBMC suspension was then diluted approximately 1:4 with PBS and 
centrifuged at 250 g for 10 minutes. The supernatant was removed and the cells were washed 
twice in 0.2% PBSA, again centrifuging at 250 g for 10 minutes. The cells could then be 





Figure 3: When diluted buffy coat is layered on top of LymphoprepTM and then centrifuged at 800 g for 25 
minutes, the erythrocytes concentrate at the bottom, below the LymphoprepTM, while the PBMCs are visible as a 
thin white layer on top of the LymphoprepTM and can be transferred to a new tube. 
 
2.7 Flow cytometry and fluorescent staining of cells 
Flow cytometry is a method that allows for rapid analysis of a high number of cells. This is 
achieved by passing one cell at a time through one or more lasers. The amount of light that 
then scatters from the cells is detected and says something about the characteristics of the 
cells (40). The amount of forward scattered light (FSC) is proportional to the size of the cell, 
and side scattered light (SSC) is proportional to the complexity. In addition, staining cells 
with fluorescently labeled antibodies specific for surface markers of interest allows for 
detection of cells that have these markers. In these cases, the cells are passed through lasers 
that are able to excite the fluorescent dyes, and the emitted light is detected by specific 
detectors. The intensity of the fluorescence from a cell is proportional to the level of 
expression of the studied surface marker. The median fluorescence intensity (MFI) in a 
sample of cells can be used to compare different samples with each other. Some flow 
cytometers can be used to perform fluorescence-activated cell sorting (FACS), where cells 
can be sorted out into tubes based on the properties analyzed by the flow cytometer. 
In this study, flow cytometric analyzes were performed on a BD LSRFortessa (Becton 
Dickinson, Franklin Lakes, NJ, USA). Cell sorting was performed on a BD FACSAria III 




To stain cells with fluorescent antibodies, cells suspended in medium or 0.2% PBSA were 
mixed with one or more antibodies at the appropriate dilution (see Table 2). The cells were 
then put on ice in the dark for 25 minutes. The cells were washed once with 0.2% PBSA and 
then resuspended in 0.2% PBSA at an appropriate volume for flow cytometric analysis, 
normally 200-500 µl. To allow for compensation of fluorochromes with overlapping emission 
spectra where no positive control was available, UltraComp eBeads (Thermo Fisher) were 
used according to the manufacturers protocol. 
 
2.8 CFSE staining and proliferation assays 
Carboxyfluorescein succinimidyl ester (CFSE) is a fluorescent dye that was used to study cell 
proliferation. Cells stained with CFSE distribute their dye equally when they divide, which is 
something that can be measured with flow cytometry to monitor proliferation within a 
population of cells that have been stimulated in some way. CFSE staining can also be used to 
distinguish certain cells from others in a culture. 
To prepare for staining, the cells were washed once in 0.2% PBSA and then resuspended in 
500 µl 0.1% PBSA (prepared by mixing PBS and 0.2% PBSA 1:1). 2 µl CFSE (250 µg/ml, 
diluted in DMSO) was added and the cells were put in a water bath holding 37°C for 10 
minutes. Approximately 5 ml cold medium was then added to the cells to stop the staining 
process and the cells were put on ice for a few minutes. The cells were washed twice with 0.2 
% PBSA and once with medium. 
Proliferation assays are a type of assay where cells are stained with CFSE before they are 
stimulated to proliferate. As the cells divide, the CFSE dye is equally distributed between the 
two daughter cells (41). When these cells are analyzed by flow cytometry, the cells that have 
divided once, twice or more times can be recognized as they appear at distinct points in the 
CFSE histogram (Figure 4). With careful dyeing and monitoring, up to 10 separate division 
cycles can be identified (42). 
In this study, the results from proliferation assays were analyzed by calculating the 
proliferation score (PS). The PS is calculated from the MFI (CFSE) in the culture of 
stimulated cells as well as in a control well of unstimulated cells by using the following 
equation: MFIstimulated = MFInonstimulated/2PS. The PS was invented by members of the 
Immunology research group, and it is defined as the median number of division of stimulated 





Figure 4 When cells are stained with CFSE and then stimulated to proliferate, it’s possible to identify which 
cells have divided a certain amount of times by looking at the peaks in the histogram showing CFSE intensity. In 
this example, CD4 T cells were stained with CFSE and then expanded in culture with irradiated feeder cells. The 
CFSE histogram shows the cells in the lymphocyte gate, where one can easily distinguish the cells that have 
divided 1, 2, 3 or 4 times although the peak to the very left also includes unstained lymphocytes in the feeder 
population.  
 
2.9 Isolation of HPA-1a specific T cell lines 
Isolation of single HPA-1a specific T cell clones has successfully been achieved at the 
Immunology research group before (37). The cells are isolated from blood samples taken 
from HPA-1a immunized women. In this project, a sample of PBMCs were used that had 
been isolated from a blood sample taken from an immunized woman (Donor 9) one month 
before a planned cesarean section. The cells had been cryopreserved since then. 
The PBMCs were thawed and rested over night. The next day, the cells were stained with 
anti-CD4 (V500) and anti-CD25 (PE) antibodies. Instead of 0.2% PBSA, they were washed 
and resuspended in a protective medium consisting of IMDM with 30% FBS and 1% 
Penicillin+Streptomycin. FACS was performed to sort all cells that were CD4+ and 
CD25intermediate into a single tube. These represent CD4 cells that have become activated, as 
they express CD25, but are not regulatory (as these express higher levels of CD25). These 
cells were then stained with CFSE and stimulated with peptide antigen. 1/3 of the cells were 
given the P33 peptide and 2/3 of the cells were given L33, both at a concentration of 5 µM. 
After 8 days, the cells were resuspended in the same protective medium to prepare them for 
sorting. The P33 stimulated cells were used as a control to compare with the L33 stimulated 
cells. Proliferating cells, as determined by decreased CFSE intensity, were single sorted out 
from the L33 stimulated cells into wells on a round-bottom 96-well plate. 240 cells in total 




each well was also provided with 100 µl feeder cell mix with anti-CD3 so that each well 
received 10 000 irradiated PBMCs and 1000 irradiated B-LCLs. The concentration of anti-
CD3 was 30 ng/ml. The following day, each well was given IL-2 at a concentration of 50 
units/ml. This was repeated every 2-3 days. If the single sorted cells proceeded to forming 





3.1 Established HPA-1a specific CD4 T cell clones demonstrated poor ability to 
proliferate 
The preliminary experiments performed during this study used different HPA-1a specific 
CD4 T cell clones previously established at the Immunology research group. These cell lines 
had previously been expanded and cryopreserved in batches. Proliferation assays with peptide 
pulsed B-LCLs were performed to confirm that the cells had maintained their specificity. The 
cells did somewhat respond to stimulation with L33 pulsed B-LCLs, which triggered a higher 
degree of proliferation than did B-LCLs pulsed with the control peptide LolP1. However, 
during these first experiments, it was observed that the cells did not proliferate as much as 
they had done in previous experiments where they had been stimulated the same way. 
Furthermore, when expanding these cells with anti-CD3 stimulation, they did not grow very 
well. 
Figure 5 shows the amount of proliferation in two batches of the same cell line, D8T106, 
stimulated with peptide pulsed B-LCLs; either L33 or LolP1. One batch (batch 1) had been 
expanded extensively and proliferated only slightly more when stimulated with L33 compared 
to LolP1. The other batch of D8T106 cells (batch 2) had not been expanded quite as many 
times and proliferated somewhat more, but not as much as would be expected upon this type 
of stimulation.  
Several different established HPA-1a specific CD4 T cell clones showed the same poor 
proliferation and response to specific stimulation. It was clear that it would be difficult to 
keep performing experiments on these cell lines if they could not be expanded further. With 
these findings in mind it was decided that various elements that may affect the efficiency of 
an expansion culture were to be investigated further in hopes of improving the expansion 






Figure 5 The HPA-1a specific CD4 T cell line D8T106 had been expanded several times since isolation and 
cryopreserved in different batches. CFSE dyed cells from two batches of these cell lines were stimulated with B-
LCLs (D4BL4) pulsed with either L33 or P33 peptide (both at 5 µM). After 5 days, their degree of proliferation, 
as determined from CFSE intensity, was analyzed by flow cytometry. Batch 1 had been expanded numerous 
times and showed very little proliferation upon stimulation with L33 pulsed B-LCLs (A). Batch 2 had also been 
expanded several times, but not quite as many and proliferated somewhat more in response to the same 
stimulation (B).  
 
3.2 Attempted isolation of HPA-1a specific CD4 T cell clones was not successful 
To gain some insight into what happens to a clonal CD4 T cell line as it is cultured and 
expanded in vitro, one aim was to isolate fresh clones to compare with the established CD4 T 
cell clones. In an attempt to isolate new HPA-1a specific CD4 T cell clones, a cryopreserved 
PBMC sample taken from an HPA-1a immunized woman was thawed and used for sorting of 
potential new clones as shown in Figure 6. When the initially sorted CD4 T cells were 
stimulated with peptide there was a significantly higher proportion of proliferating cells 
among the L33 stimulated cells compared to the P33 stimulated cells, indicating the presence 
of HPA-1a specific cells. These were single sorted and stimulated to promote proliferation. 
After approximately 14 days in culture, some of the single sorted cells had started to form 
visibly larger colonies of cells. After another week, the seven T cell clones that seemed to 
have grown best were chosen to test for HPA-1a specificity. Unfortunately, none of the clones 




lines, named D9T5 and D9T10, which grew well were kept and cultured further so that they 







Figure 6 A) A PBMC sample from an HPA-1a immunized woman was stained with anti-CD4 (V500) and anti-
CD25 (PE) antibodies. Activated non-regulatory CD4 T cells, as recognized by high CD4 and intermediate 
CD25 expression levels, were sorted from gate P4 into one tube before they were stained with CFSE, stimulated 
with peptide (P33 or L33 at 5 µM), and cultured further. B) After 8 days in culture, a significantly larger 
proportion of cells had proliferated (as determined by low CFSE fluorescence intensity) in the L33 stimulated 
batch compared to the P33 stimulated batch. From the proliferating cells in the L33 stimulated batch (gate P2), 
240 cells were single sorted into round-bottom 96-well plates and provided with feeder cells and anti-CD3 to 
stimulate expansion. 
 
3.3 Expression levels of CD28 vary significantly between different T cell clones 
To decide whether the reduced proliferation of D8T106 may be due to loss of CD28, the 
expression of CD28 was measured in batch 1 of D8T106 used for the proliferation assay 
previously described. Unfortunately, due to the fact that this experiment was performed 
months after the previously described proliferation assay, the batch 2 cells were no longer 
available. CD28 expression was also measured in the newly isolated clones D9T5 and D9T10 
in addition to three other already established HPA-1a specific T cell clones (D8T2, D8T104 
and D48T1) (Figure 7). The heavily expanded D8T106 cells were indeed found to express 
none or very low levels of CD28, which indicates that loss of CD28 expression may in fact be 
the reason for the loss of proliferative abilities by D8T106. The remaining T cell clones 
expressed comparable levels of CD28 except for D48T1, which did not express CD28. 
Surprisingly, the newly isolated clone D9T10 expressed somewhat lower levels than the other 
clones. 
 
Figure 7 Expression of CD28 was measured in six different clonal CD4 T cell lines, including a heavily 
expanded batch of D8T106. CD28 expression was detected with a PE-Cy7 conjugated antibody and the figure 





3.4 The resting expression levels of MHC II, B7-1 and B7-2 vary between different    
B-LCLs but are not fixed 
To start to understand some of the interactions that may occur between T cells and feeder 
cells in an expansion culture, the expression levels of a selection of surface molecules present 
on B-LCLs routinely used as feeder cells were studied. The expression of MHC II (HLA-DR) 
and B7-2 was measured simultaneously in eight different resting B-LCLs in three separate 
experiments (Figure 8). Analysis of the results showed that the level of both MHC II and B7-
2 expression varied between the different cell lines as well as within the same cell lines when 
samples were analyzed at different times. Some of the B-LCLs showed consistently high 
expression levels of both MHC II and B7-2 compared to some of the other cell lines. This 
included D4BL4, D8BL8 and D18BL. However, the expression levels were not fixed. On the 
third measurement, the level of B7-2 expression in D4BL4 had more than doubled from the 
two previous measurements and was more than twice as high as in any of the other cell lines. 
The first measurement of MHC II expression in D18BL also stood out as very high. D8BL7 
consistently measured very low levels of B7-2. 
 
 
Figure 8 Expression of MHC II (HLA-DR) and B7-2 (CD86) was measured simultaneously by flow cytometry 
in eight resting B-LCLs. MHC II expression was detected with an APC conjugated antibody and B7-2 with a PE 
conjugated antibody. The figure shows the mean ± SEM MFI (APC or PE) of stained triplicates minus 





The expression levels of B7-1 were measured separately for all B-LCLs except STEINLIN 
(Figure 9). Comparing these results with the B7-2 expression levels, there does seem to be 
even more variation in the expression of B7-1. It is difficult to point out one or more cell lines 
that stand out from the others in terms of expressing noticeably higher or lower levels of B7-
1. D8BL7, D48BL4 and EMJ all expressed very low levels of B7-1 when the first 
measurement was performed, but then the expression increased for the subsequent 
measurements. D8BL8 was the only cell line that seemed to have a relatively stable 




Figure 9 Expression of B7-1 (CD80) was measured by flow cytometry in seven resting B-LCLs. B7-1 
expression was detected with a FITC conjugated antibody. Measurements were performed in three separate 
experiments (only two for D48BL6), and two parallel measurements were performed for each B-LCL during 
each experiment in addition to an unstained sample. The figure shows the mean ± SEM MFI (FITC) in each 






3.5 Irradiation of B-LCLs does not significantly alter the expression of surface 
molecules 
As the B-LCLs are irradiated before they are used as feeder cells, experiments were 
performed to evaluate the effect of irradiation on B-LCLs. Cells were irradiated and the 
expression of MHC II and B7-2 was measured again with flow cytometry for four consecutive 
days. The measurements were performed before irradiation, directly after irradiation, as well 
as on each of the following three days. Figure 10 shows that within the population of live 
cells, as determined from the forward versus side scatter plot, the expression levels of MHC II 
and B7-2 stayed relatively stable. There was some variation in expression levels from day to 
day, but it did not seem to be more than what was observed in the non-irradiated cells. These 
levels were also similar to the previously measured levels. Interestingly, for both B7-2 and 
MHC II and in all eight cell lines, the expression levels decreased between the first 
measurement before irradiation and the one directly after irradiation. In the following 
measurements the levels did however increase again in some cell lines, whereas they 
continued to decrease in others. It seems as though the irradiation may have an immediate 
effect on the cells, but that the cells that are still metabolically active return to normal and 
express fluctuating levels of both MHC II and B7-2. 
When looking at the forward versus side scatter plots, the approximate percentage of live cells 
could be determined. Not surprisingly, as is shown in Figure 10C, the proportion of live cells 
decreased from day to day within all the different cell lines. By day 3, the majority of cells 













Figure 10 Expression of MHC II (A) and B7-2 (B) was measured by flow cytometry in eight different B-LCLs 
before irradiation (no irr), directly after irradiation, and once every day for the following three days. MHC II 
expression was detected with an APC conjugated antibody and B7-2 with a PE conjugated antibody. Two 
parallel measurements were performed for each sample and the figure shows the mean ± SEM MFI (APC or PE) 
in each sample minus background (MFI measured in unstained sample). The measurements used were from the 
cells in the live cells gate, as visualized in C. 
 
3.6 No B-LCL stood out as a more capable feeder cell  
Knowing that the expression levels of B7-1 and B7-2 vary between different B-LCLs, it was 
hypothesized that this could have an effect on their ability to stimulate growth of T cells in an 
expansion culture. This idea was also based on the fact that other groups had found 
differences in feeder capacity between different lines of B-LCLs (33). 
Normal expansion cultures with CFSE stained CD4 T cells isolated with MACS were set up 
using all in-house B-LCLs as feeder cells in different wells together with PBMCs. The 
amount of proliferation was analyzed on days 4 and 8 after initiation of the culture. A shift 
towards the left in the CFSE histogram indicates that the cells have proliferated more. From 
Figure 11 A, the amount of proliferation seems to be relatively similar in all wells except for 
the one with D8BL8, where the cells seemed to have proliferated slightly less than in the 
others. This can also be seen in Figure 11 B, which shows the proliferation scores. This was 
observed on both day 4 and day 8. However, in a preliminary experiment that was performed 
in a similar way to this, D8BL8 did not stand out from the other B-LCLs as a less capable 







Figure 11 MACS separated CD4 T cells stained with CFSE were expanded in flat-bottom 96-well plates with 
anti-CD3, irradiated PBMCs and one out of six different irradiated B-LCLs to determine whether any of the B-
LCLs stood out as a more capable feeder cell. On days 4 and 8 after initiation of the cultures, cells were taken 
out and analyzed for proliferation by flow cytometry. The degree of proliferation is visualized in CFSE 
histograms of the cells in the lymphocyte gate (A), and as proliferation scores (PS) calculated from the MFI 
(CFSE) of the cells in the lymphocyte gate and the MFI (CFSE) of cells that had not divided in each sample (to 




3.7 Expansion of CD4 T cells is more effective with anti-CD3 compared to PHA 
While considering the factors that may influence the success of an expansion culture, the 
question was raised as to whether the expansion protocol could be improved by replacing 
anti-CD3 with another stimulant, such as PHA. 
Parallel expansion cultures were set up following either the anti-CD3 or PHA expansion 
protocol explained in the methods section, but with the same number of CFSE stained CD4 T 
cells in each well. The CD4 T cells had been isolated with MACS. On days 4, 6, 8 and 11, 
cells were analyzed for proliferation by flow cytometry. The results are summarized in Figure 
12 A and B. The results thus show that it seems like PHA initially has a greater effect on 
proliferation than anti-CD3, but then there is a shift to more proliferation with anti-CD3. The 
results from day 4 show that a larger proportion of cells had proliferated with PHA than with 
anti-CD3. By day 6 the results were more similar and by days 8 and 11 it was clear that in 








Figure 12 MACS separated CD4 T cells stained with CFSE were expanded in flat-bottom 96-well plates with 
irradiated feeder cells and either anti-CD3 or PHA. The starting number of CD4 T cells was 80 000 in each well 
when both the anti-CD3 and PHA protocols were followed. On days 4, 6, 8 and 11 after initiation of the cultures, 
cells were taken out and analyzed for proliferation by flow cytometry. Control cells consisting of CFSE stained 
resting CD4 T cells were analyzed on day 4. The degree of proliferation is visualized in CFSE histograms of the 
cells in the lymphocyte gate (A), ans as proliferation scores (PS) calculated from the MFI (CFSE) of the cells in 
the lymphocyte gate and the MFI (CFSE) of the control cells (B). The PS values are based on the mean ± SEM 
of values obtained from triplicate wells. 
 
3.8 Expanding CD4 T cells express both stimulatory and inhibitory surface molecules 
In order to gain some more insight about the interactions that may occur between cells in an 
expansion culture and to study the effects of stimulation, surface markers present on CD4 T 
cells were studied. The expression of CD28, CTLA4 and PD1 was measured by flow 
cytometry in the same CD4 T cells expanded either with the anti-CD3 protocol or with the 
PHA protocol as described in the previous section. Measurements were performed over 
several days to determine whether expression levels stayed stable or showed some variation. 
Both anti-CD3 and PHA stimulated cells demonstrated a considerable increase in CD28 
expression compared to resting cells, which also expressed some CD28. The effect was 
greatest with PHA, which also seemed to have a longer lasting effect on the cells (see Figure 
13). While CD28 expression induced by anti-CD3 gradually decreased and was almost back 
to resting levels by day 11, expression in PHA stimulated cells stayed high for the entirety of 






Figure 13 Expression of CD28 was measured by flow cytometry in MACS separated CD4 T cells when 
stimulated with either anti-CD3 or PHA, as well as irradiated feeder cells, at day 4, 6, 8 and 11 after the 
stimulation was started. Expression in a control sample consisting of unstimulated CD4 T cells was also 
measured on day 4. CD28 expression was detected with a PE-Cy7 conjugated antibody. Triplicate measurements 
were performed for each sample and the figure shows the mean ± SEM MFI (PE-Cy7) for each sample. 
 
Like CD28, expression of PD1 was also increased by stimulation with both anti-CD3 and 
PHA (see Figure 14). However, in this case the expression in resting cells was close to zero. 
Again the effect of PHA was greater than that of anti-CD3, and as with CD28, the expression 
of PD1 gradually decreased after stimulation with anti-CD3. Expression in cells stimulated 
with PHA also decreased, but not as quickly as in the anti-CD3 stimulated cells. Only by day 






Figure 14 Expression of PD1 was measured by flow cytometry in MACS separated CD4 T cells when 
stimulated with either anti-CD3 or PHA, as well as irradiated feeder cells, at day 4, 6, 8 and 11 after the 
stimulation was started. Expression in a control sample consisting of unstimulated CD4 T cells was also 
measured on day 4. PD1 expression was detected with a PE conjugated antibody. Triplicate measurements were 
performed for each sample and the figure shows the mean ± SEM MFI (PE) for each sample. 
 
The results from measurements of CTLA4 are not shown as neither anti-CD3 nor PHA 
stimulated cells seemed to express it at any time points. 
 
3.9 Resting B-LCLs do not express PD-L1  
Expression of PD-L1 was initially measured in all eight B-LCLs at the same time as MHC II 
and B7-2. When these measurements were performed, the cells had not been stimulated or 
otherwise treated in any way. The results are presented in Figure 15 and show that none of the 
eight cell lines seemed to express PD-L1 when resting as there was close to no difference in 
fluorescence intensity between stained and unstained cells. This result also showed that the 
used antibody produced very little background fluorescence caused by unspecific binding. 
It was hypothesized that the presence of CD4 T cells might be able to induce expression of 
PD-L1 in the B-LCLs. To test this two of the cell lines were cultured with CD4 T cells in a 
1:1 ratio for two days before new measurements were performed, but the results were 






Figure 15 Expression of PD-L1 was measured by flow cytometry in eight different lines of resting B-LCLs 
stained with an antibody targeting PD-L1 (eFluor 450 conjugated anti-CD274). The figures show histograms of 
eFluor 450 fluorescence in the live cells gate for both stained and unstained cells. MFI (eFluor 450) values are 




3.10 Expression of PD-L1 can be induced in B-LCLs 
Despite the fact that the initial results indicated that B-LCLs do not express PD-L1, some 
more experiments were performed to confirm this result. Surprisingly it was found that 
expression of PD-L1 was actually induced in some B-LCLs when these were used as feeder 
cells to expand CD4 T cells. Staining the B-LCLs with CFSE before mixing them with the 
other cells in an expansion culture made it possible to later distinguish them from the others 
and measure PD-L1 expression. Figure 16 shows a case where this was performed in an 
expansion culture set up following the regular anti-CD3 protocol. After three days, both 
D18BL and D48BL6 seemed to have started expressing PD-L1 as the difference between 
stained and unstained samples now was noticeably higher than previously. It is worth 
mentioning that when this experiment was performed, the laser settings in the flow cytometer 




Figure 16 Expression of PD-L1 was measured by flow cytometry in the B-LCLs D18BL and D48BL6 when 
they were used as feeder cells in an expansion culture. The cells had been stained with CFSE and irradiated 
before they were mixed with CD4 T cells and irradiated PBMC. After 3 days in culture, cells were resuspended 
and some were stained with eFluor 450 conjugated anti-CD274 and some were left unstained. The figure shows 
histograms of eFluor intensity in stained versus unstained cells in the CFSE positive gate of the live cells. 






To confirm that what looked like expression was real and not due to the changed flow 
cytometry settings or any unknown circumstantial factors, the experiment was repeated in a 
few variations. It was again postulated that it was the CD4 T cells that induced the expression 
of PD-L1, but that they had to be activated and not resting. To determine whether this was the 
case, some cultures were prepared with only B-LCLs, CD4 T cells and anti-CD3. Normal 
expansion cultures were also set up again. Additionally, to get an idea of how soon the B-
LCLs started expressing PD-L1, measurements were performed at different time points after 
initiation of the culture. 
Contrary to what was hypothesized, it did not look like it was the activated CD4 T cells that 
induced the expression of PD-L1. Only the culture that contained PBMCs in addition to B-
LCLs and CD4 T cells resulted in a significant increase in PD-L1 expression. Interestingly, 
not all the B-LCLs present in the culture started expressing PD-L1. Two clear populations 
could be distinguished in the histogram; one negative and one positive for PD-L1 expression 
(Figure 17). When PBMCs were present, expression of PD-L1 was observed already after one 
day. Without PBMCs, no expression was detected even after 3 or 4 days, indicating that one 





Figure 17 CFSE stained D18BL were irradiated and mixed with different combinations of CD4 T cells, anti-
CD3 and IL-2. The cultures were stained with an anti-PD-L1 antibody (eFluor 450) and expression by D18BL 
was detected by first gating on all live cells and then on CFSE positive cells as shown in A. The PD-L1 
expression by D18BL in the different culture combinations is visualized in B along with the MFI (eFluor 450). 
The cultures measured after 0 hours, 6 hours and on day 1 all contained CD4 T cells and anti-CD3 in addition to 
D18BL. The culture with PBMCs contained the same in addition to irradiated PBMCs. The control cultures 







By performing a variety of different experiments, some important insights about the 
conditions of a T cell expansion culture have been gained. The interactions that may occur 
between the T cells and the feeder cells have been studied and several questions have been  
answered at the same time as many new questions have appeared.  
 
4.1 Optimal culturing and use of CD4 T cell lines 
The early results from this project showed that HPA-1a specific T cell lines that had been 
expanded numerous times had more or less stopped responding to stimulation with specific 
antigen as well as stimulation with anti-CD3 and IL-2, which normally leads to massive 
proliferation of all CD4 T cells regardless of specificity. Likely, the reason for the decreased 
proliferation was that the cells had reached the stage of immunosenescence, which we know 
can affect T cells in vivo, but also in vitro when they have proliferated extensively (21, 43). 
As loss of expression of CD28 is one of the hallmarks of T cell immunosenescence (21), it 
was not surprising to find that the heavily expanded batch of D8T106 cells did not express 
detectable levels of CD28. As expected, the newly isolated clones did express CD28. Keeping 
track of CD28 expression by T cell clones could thus be important when culturing T cells in 
the future. However, it is worth mentioning that the established T8T2 clone, which also 
expressed close to zero CD28, has since been shown to grow well in expansion cultures. As 
mentioned in the introduction, immunosenescence could also be a result of for instance 
decreased telomerase activity. 
These first results sparked an interest in studying and possibly improving the culturing 
methods currently used to expand CD4 T cells at the Immunology research group. Perhaps an 
improved expansion protocol could help in taking care of future HPA-1a specific CD4 T cell 
clones. However, it is important to keep in mind that if a single T cell clone is only capable of 
dividing a certain amount of times before it reaches the stage of immunosenescence, then 
optimizing the culture conditions for better growth will only lead to this stage sooner. Having 
a well thought out plan for the specific experiments one wants to perform on a certain T cell 
clone is essential. 
Having experienced that isolation of new HPA-1a specific T cell clones is not easy, that 




new HPA-1a specific T cell clones during this project had been obtained from an HPA-1a 
immunized woman at the end of her pregnancy and should in theory have contained quite 
many HPA-1a specific CD4 T cells. This also seemed to be the case when comparing the P33 
stimulated cells to the L33 stimulated cells, where a significantly higher proportion of cells 
had proliferated within the latter sample. Still, out of 240 single sorted proliferating cells, only 
a handful grew to larger colonies and out of these, none responded to stimulation with L33 
peptide or L33 pulsed B cells. This makes it very clear that the HPA-1a specific CD4 T cell 
clones that successfully are isolated are very valuable, that they should be taken well care of, 
and that one should avoid “wasting” these cells. 
The cells are clearly isolated so that one can use them in experimental assays, but many such 
assays lead to loss of the cells afterwards. When performing assays that for instance involve 
flow cytometry analysis, the cells cannot be reused after the assays are performed. Perhaps a 
strategy could be to only use cells that have expanded several rounds already in experiments 
so as to not “waste” cells that could still proliferate actively and give rise to many more cells. 
Ideally the cells used in experiments would be cells that are only capable of dividing a few 
more times, but still have not become immunosenescent. Understandably, it would be difficult 
to know exactly when the cells are at this stage, but keeping track of how many times a 
certain cell line has been expanded is certainly a start.  
Unfortunately no new HPA-1a specific T cell clones were isolated in this study, but two 
control cell lines were obtained. We do not know which antigens these cell lines are specific 
for, but knowing that they do not recognize HPA-1a means that they can be used as negative 
control cells during future experiments to compare with cell lines that are HPA-1a specific. 
 
4.2 Expression and effect of B7-1 and B7-2 in feeder cells 
To start to understand the conditions that may affect the outcome of a CD4 T cell expansion 
culture, it seemed important to learn more about the cells used as feeder cells and how they 
may stimulate or possibly inhibit growth. In this study, we chose to focus on the B-LCLs. 
There is some uncertainty about the exact roles of B-LCLs when used as feeder cells together 
with PBMCs. As with all feeder cells, one of the main roles is certainly to create a more dense 
cell layer as we know that most cell types require this for optimized growth (29). Another 
suggested role of B-LCL feeder cells is that they can provide the T cells with the 




may bind to CD28 on the T cells. There is reason to believe that costimulation can be of 
importance for expansion of T cells as experiments have been reported where cells stimulated 
with anti-CD3 and anti-CD28 demonstrated significantly better proliferation than cells treated 
with only anti-CD3 and IL-2 or PHA and IL-2 (34). Anti-CD3 stimulation alone has also been 
shown to induce anergy in some T cells (20). 
In light of this, it was interesting to find that the levels of B7-1 and B7-2 expression varied 
quite a lot between different lines of B-LCLs. In particular, there were clear differences in the 
levels of B7-2 expression, whereas B7-1 expression seemed to fluctuate more. It was 
suggested that the levels of B7 expression could have an effect on the stimulatory effects of 
the B-LCLs when used as feeder cells. Whether this effect would be negative or positive was 
however not clear. As we know, B7-1 and B7-2 are stronger binders of the inhibitory T cell 
marker CTLA4 than of CD28, so it would be the expression of these on the T cells that would 
determine the effect of B7. As others have suggested, feeder cells expressing B7-1 and/or B7-
2 may actually inhibit proliferation of T cells (34). A report from 1997 presented a method for 
expanding T cells without feeder cells for the sake of avoiding unwanted interactions (34). 
Instead of feeder cells, they only provided the T cells with beads coated with anti-CD3 and 
anti-CD28 antibodies. This method resulted in very efficient growth of the cells. In contrast, 
when the expression of CD28 and CTLA4 was measured on expanding CD4 T cells in this 
study it was found that CD28 was significantly up regulated, whereas CTLA4 expression 
could not be detected. If interaction with B7 on feeder cells plays a role in expansion cultures 
this would suggest that the B-LCLs expressing the highest levels of B7 would be the best 
suited feeder cells. One would perhaps expect that D8BL7, which consistently expressed very 
low levels of B7-2 and relatively low levels of B7-1 would be a worse suited feeder cell than 
for instance D8BL8 or D4BL4. However, as we saw, there was no clear difference in 
proliferation of CD4 T cells when expanded with use of different B-LCLs as feeder cells. 
D8BL8, which expressed high levels of both B7-1 and B7-2 did in fact lead to less 
proliferation than any of the other cell lines, although that was only observed once. D4BL4, 
which expressed similarly high levels of B7-1 and B7-2 compared to D8BL8 did not stand out 
as either a particularly good or bad feeder cell. This seems to indicate that the levels of B7 
expression by feeder cells may not be important for their ability to stimulate proliferation. 
Whether this means that there is no interaction between B7 and CD28 is not certain. It could 




necessary costimulation. Perhaps because when an expansion culture is started, the number of 
B-LCLs is usually twice the number of T cells. 
Another option is that the expression of B7-1 and/or B7-2 may in fact be changed when the 
cells are in the expansion culture. We have seen that irradiation does not significantly change 
the expression patterns, but now that we know that expression of PD-L1 by B-LCLs changes 
when they are in the expansion culture, this may also be the case for B7-1 and B7-2. In the 
report that first described the expression patterns of B7-2, it was in fact found that stimulated 
T cells could increase expression of B7-2 on B cells, although in this study the B and T cells 
had been stimulated with concanavalin A, and not anti-CD3 (44). In another study B cells 
were cocultured with CD4 T cells that had been pre-activated with anti-CD3, and this led to 
higher expression of B7-1 by the B cells (45). In hindsight, it may have been more beneficial 
to measure the expression of B7-1 and B7-2 on our B-LCLs after they had been in an 
expansion culture for a few days. 
When discussing the expression of B7-1 and B7-2, another aspect that may be interesting to 
consider is the fact that although B7-1 and B7-2 often are thought of as two molecules that 
perform the same functions in a cell, they do in fact only share 25% homology (46), and their 
expression is regulated independently of each other (44). B7-2 expression is more rapidly 
upregulated in APCs than B7-1. In addition, it has also been shown that even though both B7-
1 and B7-2 provide costimulation of T cells through CD28 and inhibition through CTLA4, the 
regulation of this may not work exactly the same way for these two molecules. In an article 
from 2003, Samson et al. argued that B7-2 may favor binding to CD28 over CTLA4, whereas 
B7-1 favors binding to CTLA4 (47). This argument was based on some of the structural 
differences that have been found between B7-1 and B7-2. They also presented the idea that 
B7-1 is the initial ligand, which maintains immune tolerance through binding to CTLA4, but 
then this interaction can be surpassed by upregulation of B7-2 expression by APCs when they 
encounter antigen. Since expression of B7-1 and B7-2 was measured with antibodies 
conjugated to different fluorochromes, it was not possible to say from the results obtained in 
this study if the expression of one of them was significantly higher than the other. Whether 
the relative expression levels of B7-1 and B7-2 mean anything for an expansion culture is 
hard to say. As already mentioned, expression of CTLA4 was not detected in our cultures, so 





4.3 Expression levels of MCH II on B-LCLs vary greatly among different B-LCLs as 
well as within the same cell line 
The B-LCLs studied in this project were cultured the same way, without addition of any 
cytokines and the measurements of MHC II expression that were performed should therefore 
represent their resting expression levels. The levels of expression varied within the same cell 
lines, although some kind of consistency was observed. This finding was more or less 
expected as we know from the literature that mature resting B cells constitutively express 
relatively high levels of MHC II, as well as class I, but the levels are not fixed and various 
factors can affect the expression (48, 49). The cytokine IFNγ as well as bacterial molecules 
like lipopolysaccharides can enhance the level of MHC II expression in B cells (49). This 
should however not have affected the B-LCLs in this study as they were cultured separate 
from other cells and stimuli. 
There seemed to be less variation between the different cell lines in their expression of MHC 
II than of B7, but there was still some difference to be observed. While the expression levels 
of B7-1 and/or B7-2 were hypothesized to have an effect on activation when the T cells are 
unspecifically activated in an expansion culture, the levels of MHC II expression may affect 
the ability to activate T cells when presenting specific antigen. In vivo, the level of MHC II 
expression in different tissues directly influences the level of T cell activation at these sites 
(50). Knowing this, it is possible that some of the B-LCLs that were found to consistently 
express relatively high levels of MHC II could be more efficient at activating T cells when 
presenting the antigen that the T cells are specific for. This hypothesis was however not tested 
during this project, but the information about MHC expression levels among the different B-
LCLs could be valuable for future experiments. 
 
4.4 Effects of irradiation  
When B-LCLs were used as feeder cells in expansion cultures they were exposed to 
irradiation to inhibit their proliferation. But as previously mentioned, very little in-depth 
information about what really happens to a cell after it has been irradiated is available in the 
literature. The metabolism eventually decreases, and as was seen from the results obtained in 
this project, the majority of cells seem to die within the first few days after irradiation. The 
fact that the cells eventually die from the irradiation was known, but exactly how fast it 




growing for up to 14 days before they hit a plateau and proliferation stops. It was surprising to 
see that most of the B-LCLs die after only a few days. As could be seen from the results, the 
cells analyzed here did not consist of 100 % live cells to begin with, so exactly how long it 
takes before a population of 100 % live cells turns into 100 % dead cells could not be 
determined. Naturally, dead cells cannot release any stimulatory cytokines or interact with the 
expanding T cells, so the fact that the T cells keep growing even after the majority of feeder 
cells are dead must be a result of some other stimulation. It is possible that the increased cell 
density resulting from the proliferation of T cells stimulates them to keep proliferating. The 
IL-2 produced by the T cells as well as the added IL-2 also stimulates proliferation. When the 
proliferation stops, this may be because the anti-CD3 is used up in addition to being removed 
when cells are provided with fresh medium. 
When looking at the expression of surface markers by irradiated B-LCLs, it was not clear how 
the results should be interpreted. As was seen from the resting B-LCLs, the expression of both 
MHC II and B7-2 seems to fluctuate quite a bit, so when expression levels changed after 
irradiation it was not obvious whether this was natural or due to the irradiation. It may have 
been beneficial to analyze more surface markers, and perhaps some that are more steadily 
expressed, to see if a general trend can be found. It may seem logical to think that breaks in 
the DNA caused by irradiation would lead to altered expression of surface molecules, but as 
we have seen it does not seem like that is the case. At least not in the cells that still appear to 
be alive. The fact that the expression of both MHC II and B7-2 increased in some cell lines 
after irradiation demonstrates the fact that many cells stay metabolically active even after 
irradiation. This fact was also demonstrated by the fact that expression of PD-L1 could be 
induced in cells after they had been irradiated. 
 
4.5 Differential effects of anti-CD3 and PHA on proliferation 
Compared to the uncertainty around the importance of costimulation, or signal 2, for 
expansion of T cells, there is definitely more certainty connected to the importance of the first 
signal; the activation of the TCR, which is absolutely necessary. The two options for 
providing this stimulation that were looked at during this study seemed to affect the T cells 
differently.  
Colleagues in Amsterdam had reported great expansion success with using PHA to expand 




the Immunology research group numerous times. This same clone had also grown well with 
the conventional anti-CD3 expansion methods at the Immunology research group, but 
recently started to show poor proliferation capacities like several other clones.  
Based on this as well as on the fact that PHA is known to be a more potent stimulator than 
anti-CD3 (27), it was expected that the T cells expanded with PHA would proliferate more 
than those stimulated with anti-CD3. There are not a lot of reports available that directly 
compare the abilities of PHA and anti-CD3 to stimulate proliferation of T cells, but those that 
do generally report more proliferation with PHA (51-53). In one study, it was found that anti-
CD3 was more effective than PHA for stimulating memory cells, whereas naïve T cells 
responded better to PHA (24). The CD4 T cells expanded in the present study should contain 
both cell types, whereas the HPA-1a specific T cell clones are neither naïve nor memory, 
which makes it difficult to say what this may indicate for our expansion cultures. 
The results obtained from this study did not suggest that the PHA protocol for expansion is 
more effective than the already established anti-CD3 expansion protocol. For improved 
expansion in the future, there may be other changes that could be made. The use of anti-CD28 
in addition to anti-CD3, coating plates with anti-CD3, or using beads coated with anti-CD3 
and anti-CD28 may be better options than PHA. Knocking out PD-L1 or other inhibitory 
molecules in feeder cells may also be an option (discussed in detail later). 
It is important keep in mind that the protocols used for expanding cells with either PHA or 
anti-CD3 in this study used different amounts of feeder cells. This could be the reason why 
the anti-CD3 expansion seemed more effective. For a direct comparison of the stimulatory 
effects of PHA and soluble anti-CD3, it would probably have been more accurate to use the 
same number of feeder cells and the same amount of IL-2. However, in this study, the 
objective was to compare the expansion methods routinely used by two different research 
groups rather than anti-CD3 and PHA specifically.  
 
4.6 The effects of anti-CD3 and PHA on expression of immune checkpoint molecules 
It was known that PHA is a more unspecific stimulator than anti-CD3 as it is able to bind to 
several cell membrane glycoproteins in addition to CD3 (27). The fact that PHA is such a 
strong activator is likely the reason why the levels of both CD28 and PD1 were noticeably 




good thing is however not obvious. Higher CD28 could lead to better costimulation while 
higher PD1 could lead to inhibition.  
The expression of  PD1 was expected to be found, as T cells are known to express it upon 
stimulation trough the TCR (15). An article from 2005 also reported on the effects of anti-
CD3 versus PHA stimulation of cells on the expression of PD1 (54). Similar to what was 
found here, they also saw that PHA led to a higher degree of PD1 expression than anti-CD3. 
In their results, the highest expression levels were found at 72 h for anti-CD3 stimulated cells 
and at 72-96 h for PHA stimulated cells. This also correlates with the results found here as 
levels decreased after day 4, but since this was the first day of measurement, we cannot say 
exactly when the expression was at its highest. Nevertheless, the fact that PD1 expression was 
found at all means that interaction with PD-L1 expressed by feeder cells is possible. 
Having seen that PHA leads to higher expression of both CD28 and PD1 than anti-CD3 
probably means that it induces high expression levels of other markers as well. Still, 
expression of CTLA4 was not detected in neither anti-CD3 nor PHA stimulated cells. This 
was somewhat unexpected as activated T cells are usually known to express CTLA4 (14). 
However, a study from 2004 that looked at CTLA4 expression in freshly isolated CD4 T cells 
stimulated with PMA and ionomycin found that the expression levels peaked after only four 
hours and then gradually decreased again (55). As our first measurements were performed on 
day 4 it may very well have been that the cells did express CTLA4 at some point before this. 
However, if that was the case, it did not seem like it had a significant impact on proliferation 
as the cells continued to proliferate for the entirety of the 11 days that the experiment lasted. It 
may still have been useful to perform a measurement of expression of all markers at an earlier 
time point. Both to see if CTLA4 could be detected and to see if higher expression levels of 
CD28 and PD1 could be revealed.  
 
4.7 Induced expression of PD-L1 in B-LCLs 
The initial results with resting B-LCLs indicated that they do not express PD-L1 at all. The 
fact that co-culturing them with CD4 T cells did not lead to PD-L1 expression either 
reinforced this finding. Therefore, it was a great surprise to find that the B-LCLs did in fact 
express PD-L1 after all, but only when used as feeder cells in expansion cultures with CD4 T 
cells and irradiated PBMCs. We know that expression of PD-L1 is induced in B cells when 




that neither activated nor resting CD4 T cells cultured with the B-LCLs led to expression of 
PD-L1 indicates that it must have been one or more cell types present within the PBMCs that 
induced the expression. It would have been interesting to find out which cells had this effect 
and if they could induce it alone or if the expression was a result of being in a culture with 
many different cell types. One way to try to determine this would be to repeat the experiments 
performed in this study, but using PBMCs depleted for one cell type, for instance monocytes, 
natural killer cells, CD8 T cells or B cells. Unfortunately, due to time restraints, it was not 
possible to perform such an experiment. 
As could be seen from the histograms displaying PD-L1 expression, there was a high degree 
of autofluorescence in the unstained samples, probably due to the large size of the B-LCLs as 
well as the flow cytometry channel used for the eFluor 450 conjugated antibody. This made it 
somewhat difficult to interpret the early results and it was not obvious whether these cells 
expressed some PD-L1 or none at all. However, the clear positive population that appeared 
when B-LCLs were cultured with PBMCs but not without them clearly indicated an increased 
expression in some cells. For future experiments it may however be beneficial to utilize an 
antibody conjugated to a fluorochrome that is not associated with such a high degree of 
autofluorescence. An isotype control antibody could also be used to compare with to make 
sure that observed expression is not due to unspecific binding. 
 
4.8 Effects of PD-L1 present in expansion cultures 
Knowing that expanding T cells upregulate their expression of PD1 and that B-LCLs express 
PD-L1 when in an expansion culture, there is reason to believe that interaction between these 
two molecules occur in expansion cultures. However, there are very few articles that report on 
the effects of PD-L1 on proliferation of T cells in vitro not in relation to cancer. Freeman et 
al., who were the first to identify the PD-L1 molecule, performed a selection of experiments 
on the effects of PD-L1 on proliferation of T cells (15). Among other things, they found that 
the proliferation of T cells stimulated with anti-CD3 was inhibited when PD-L1 was also 
present. These experiments used beads coated with anti-CD3 and PD-L1 instead of feeder 
cells, but they still represent conditions that are similar to the conditions that our T cells 
experience during expansion. Therefore there is reason to believe that PD-L1:PD1 interaction 




Interestingly, Freeman et al. also found that if cells received enough costimulation through 
CD28, then they could resist the inhibitory effects of PD-L1 (15). This again sparks an 
interest in measuring the expression of B7 in feeder cells when actually in the expansion 
cultures. It is possible that our T cells are not affected by the presence of PD-L1. 
 
4.9 Knocking out PD-L1 in B-LCLs may improve feeder capacities 
To study the effects of PD-L1 on B-LCLs used as feeder cells, the idea to use CRISPR/Cas 
genome editing to knock out the gene encoding PD-L1 in one or more strains of B-LCLs was 
created. PD-L1 knock out in antigen presenting cells used as feeder cells is something that has 
not previously been reported. It is therefore not certain what the effects of it would be. As 
already mentioned, PD-L1 may not play any role in expansion at all. 
PD-L1 interactions are thoroughly studied in relation to cancer as many cancer cells express 
this ligand as a way of avoiding immune responses that may kill them (56). This has led to the 
development of new cancer immunotherapies based on the inhibition of the interaction 
between PD-L1 on the cancer cells with PD1 on tumor infiltrating lymphocytes. For obvious 
reasons, it is not possible to knock out PD-L1 in tumor cells inside the body by use of 
CRISPR/Cas technology. Instead, an option is to knock out the gene encoding PD1 in T cells 
in vitro and then reintroduce the cells to the body (19). Another option is to use antibody 
blockade, where anti-PD-L1 antibodies are administered to the cancer cells so that they can 
bind to PD-L1 and thereby inhibit it from binding to PD1 on the T cells. This may also be an 
option for in vitro culturing or to simply determine whether PD-L1 expression plays a role in 
expansion cultures. However, if it does play a role, then knocking the gene out permanently 
would seem more cost effective in the long run.  
Both knock out of PD1 and use of PD-L1 blocking antibodies has shown promising results in 
terms of increased proliferation and survival of T cells in relation to cancer immunotherapy 
(19). With this in mind, there is reason to believe that will be the case for T cells in expansion 
cultures as well. However, another interesting point is that some studies have reported that 
PD-L1 can have positive effects on T cell proliferation under certain conditions (13, 57). One 
study found that when the TCR signal is low, PD-L1 and PD-L2 had costimulatory effects on 
T cells (13). Anti-CD3 and PD-L1 together has also been found to result in increased 
secretion of IL-10, IFN-γ and GM-CSF (13). These results indicate that the PD-L1 and PD-L2 




two different receptors, one of which is stimulatory and the other is inhibitory (13). Taking 
this into consideration, it may be possible that knocking out PD-L1 in cells used to promote 
growth of T cells actually has a negative effect. 
  
4.10 hTERT transfection of cells may be an option for better proliferation 
Completely unrelated to interactions with feeder cells and expression of costimulatory 
molecules, there may exist another option for improved culturing of specific T cell clones. As 
explained in the introduction, a possible explanation for the decreased ability of a cell line to 
proliferate may be shortening of their telomeres; the short DNA repeats at the end of 
chromosomes that protect their integrity during replication. The enzyme telomerase functions 
to add telomeric repeats to chromosomes and is encoded by the hTERT gene (58). An option 
discussed during this study was to transfect the poorly proliferating T cell clones with this 
gene to see if that would increase their proliferative abilities. Lymphocytes are in fact among 
the few human cell types that naturally express this gene, and the telomerase activity has been 
found to be upregulated upon activation of lymphocytes (59). Therefore, hTERT transfection 
may seem unnecessary, but as we have seen, lymphocytes expanded in vitro do eventually 
reach a state of cellular senescence, which may or may not be caused by shortened telomeres. 
Furthermore, other groups who have transfected T cells with hTERT have achieved 
successful results in terms of improved proliferative abilities (60, 61).  
However, due to lack of experience with this type of transfection as well as uncertainties 
about the possible effects of it, this was not prioritized. Ideally we do not want to change the 
isolated cells in any way as it may affect the cell’s characteristics in unexpected ways. 
Existing reports do however describe unchanged cytokine profiles and antigen specificities in 
transfected CD4 T cells (60). One study looked at CD28 expression in hTERT transfected 
CD8 T cells and found that they, like untransfected cells, eventually stopped expressing 
CD28, but were still able to proliferate extensively (61). This indicates that even though the 
problem with cellular senescence of T cells may be due to lack of CD28 expression, this 
problem could be surpassed by transfecting the cells with hTERT. Transfection of HPA-1a 






The insights gained from this study have sparked an interest in understanding how CD4 T 
cells work, not only in relation to disease and immune responses, but also in everyday 
culturing and maintenance. We have experienced that clonal CD4 T cells eventually reach a 
point where their ability to proliferate is noticeably reduced, possibly due to loss of 
expression of CD28.  
By studying some of the conditions of a standard CD4 T cell expansion culture, we have 
learned that the T cells increase their expression of both the stimulatory receptor CD28 and 
the inhibitory receptor PD1. The increase is greater when cells are stimulated with PHA than 
with anti-CD3. The B-LCLs that the T cells are cultured with express B7-1 and B7-2, which 
can bind to CD28, and the expression of the PD1 ligand PD-L1 is induced when B-LCLs are 
in an expansion culture. 
In terms of stimulating proliferation of CD4 T cells, it did not seem like the levels of B7 
expression played a significant role, which meant that different B-LCLs had similar 
stimulatory effects. When considering different options for the activation of the TCR, anti-
CD3 seemed more effective at stimulating proliferation than PHA in the long run. 
To conclude, some of the lessons learned from this study could hopefully be considered to 
establish better routines for culturing of CD4 T cells in relation to future work at the 




5 Future Perspectives 
The work performed in association with this study has given some insights into the conditions 
of a CD4 T cell expansion culture. Still, there are many unanswered questions.  
As already mentioned, studying the expression of B7-1 and B7-2 by feeder cells in expansion 
cultures to see if it is altered, like PD-L1, could be interesting. 
One objective that will be pursued in the near future is to perform a CRISPR/Cas knockout of 
the PD-L1 gene in one or more of the B-LCLs. To make sure that the knock out is successful, 
the cells would then have to be stimulated in an expansion culture as before to determine 
whether the expression has disappeared. New parallel expansion cultures could also be set up, 
using the PD-L1 knock out cells in some wells and the original PD-L1 expressing cells in 
others. The amount of proliferation in these two systems could then be compared with each 
other to see if the knock-out had any effect. As mentioned it would also be interesting to try to 
determine exactly which cells or which interactions it is that cause the PD-L1 expression by 
B-LCLs. 
As described in the introduction to this study, there exists several different checkpoint 
molecules and ligands that can be expressed by T cells and APCs. This study did not look into 
the expression of surface markers by PBMCs used as feeder cells, but that could also be 
interesting to study. Regarding inhibitory checkpoint molecules expressed by B-LCLs, this 
study focused on PD-L1, but there are other such molecules that could also be interesting to 
study closer, for instance GAL9. The expression of LAG3 and TIM3 on expanding T cells 
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